All Drug Discovery articles
-
NewsAI and genetics identify WNK2 inhibitor for osteoarthritis treatment
Researchers at University of Utah Health have used artificial intelligence and human genetic data to identify a promising early-stage drug candidate targeting WNK2, a protein linked to inherited osteoarthritis, with the lead compound reducing inflammatory gene activity and supporting cartilage cell health in laboratory models.
-
NewsNew molecular glue platform broadens E3 ligase targeting for cancer drug development
Researchers at Dana-Farber Cancer Institute have developed a scalable platform for discovering molecular glue degraders, reporting the first metabolically activated example and broadening the scope of targeted protein degradation in cancer.
-
NewsWhat Google’s AI talent exodus could mean for future drug discovery
The departure of leading AI researchers from Google to found Discovery Loop raises important questions about the future direction of artificial intelligence in scientific research and drug development.
-
NewsTargeting the roots of head and neck cancer: Why MDA-9 matters
A small molecule inhibitor developed at Virginia Commonwealth University has demonstrated the ability to eliminate cancer stem cells and reverse cisplatin resistance in preclinical models of head and neck squamous cell carcinoma, offering a potential new strategy to address one of oncology’s most persistent clinical challenges.
-
NewsWhat Oblenio’s Phase I trial means for autoimmune drug discovery
Oblenio Bio has dosed the first patients in a Phase 1a trial of LBL-051, a tri-specific T cell engager designed to simultaneously target CD19, BCMA and CD3 and eliminate both B cells and plasma cells in a bid to achieve durable immune reset in refractory autoimmune diseases.
-
ArticleWhy inherited retinal disease treatment requires more than gene therapy
Most inherited retinal diseases still have no approved therapy despite advances in gene therapy. This article explores why researchers are targeting shared disease mechanisms alongside individual mutations.
-
NewsTriple drug combination targets cancer and senescent cells simultaneously
A three-drug combination targeting shared metabolic vulnerabilities in cancer and senescent cells has improved physical performance and extended survival in aged mice, whilst avoiding the thrombocytopenia associated with existing navitoclax-based regimens.
-
NewsMitochondrial microprotein discovery reveals new Type 2 diabetes genetic link
A newly identified mitochondrial microprotein, MENTSH, has been linked to increased Type 2 diabetes susceptibility in Mexican and Mexican American populations, pointing towards a potential precision medicine target.
-
NewsInsilico Medicine launches AI drug discovery benchmarking platform
Insilico Medicine has unveiled a benchmarking platform designed to assess whether AI models can perform genuine drug discovery tasks, using decontaminated real-world datasets and proprietary validated programmes to move beyond inflated benchmark scores.
-
NewsFullscope-seq maps transcript isoforms with spatial single-cell resolution
Researchers have developed Fullscope-seq, a long-read spatial transcriptomics platform that maps alternative transcript isoforms within intact tissues at single-cell resolution – opening new possibilities for target identification and precision biomarker discovery.
-
ArticleWhy the blood–brain barrier blocks most drugs – and how ultrasound could help
The blood–brain barrier protects the brain from harmful substances, but it also prevents many medicines from reaching their target. Researchers are investigating whether focused ultrasound could safely improve drug delivery.
-
NewsResearchers develop AI system to accelerate tuberculosis drug discovery
Researchers at Texas A&M have developed AI-driven platforms to help scientists navigate the bottlenecks of tuberculosis drug discovery, from eliminating nuisance compounds to unlocking years of archived research data.
-
ArticleInside one of the most comprehensive human proteome atlases to date
Understanding where proteins are expressed throughout the body is critical for selecting better drug targets. Here’s how a new human proteome atlas could improve target selection, predict toxicity and support drug repurposing.
-
NewsBlood test for protein misfolding identifies Alzheimer’s risk years before symptoms
A blood-based biomarker measuring amyloid beta protein misfolding has demonstrated superior predictive accuracy for pre-symptomatic Alzheimer’s disease compared with p-tau 217, achieving an AUC of 0.87 when combined with genetic and demographic data.
-
NewsHow dendritic cells organise tumour immunity – and why drug developers should take notice
A new study published in Science identifies a specialised dendritic cell subset as the cellular architects behind tertiary lymphoid structures, offering a potential new target for boosting anti-tumour immunity and converting immunologically cold tumours into treatment-responsive ones.
-
ArticleAI’s promise and practical limits in drug discovery
From ChatGPT to AI agents and world models, where is AI really heading in drug discovery? Dr Raminderpal Singh explains what researchers should focus on now.
-
NewsLandmark fibromyalgia study highlights neurological targets for new therapies
A landmark genome-wide study of more than 2.5 million adults has identified 26 genomic regions linked to fibromyalgia, confirming a neurological basis for the condition and opening new avenues for targeted drug discovery.
-
NewsDoxycycline found to disrupt bacterial ribosomes via two unknown mechanisms
Researchers have identified two previously unknown mechanisms by which doxycycline inhibits bacterial protein synthesis, findings that could inform the design of next-generation antibiotics against drug-resistant pathogens.
-
WebinarOligonucleotide therapeutics safety considerations across drug development
As oligonucleotide therapeutics rapidly advance, their safety profile presents challenges unlike any other drug modality. Discover how nonclinical safety studies, regulatory expectations and real-world case examples can help you navigate these challenges with greater confidence.
-
NewsAmino acid sensor discovery could unlock new targeted cancer therapies
Researchers have uncovered how cells sense amino acids and activate the mTORC1 growth pathway, identifying LARS1 phosphorylation as a critical upstream switch with implications for more precise cancer drug development.